Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial

Journal of Diabetes

Volumn 8, Issue 3, 2016, Pages 405-413

  Jin, Sang Man ^a   Kim, Jae Hyeon ^a   Min, Kyung Wan ^b   Lee, Ji Hyun ^e   Ahn, Kue Jeong ^d   Park, Jeong Hyun ^g   Jang, Hak Chul ^h   Park, Seok Won ⁱ   Lee, Kwan Woo ^j   Won, Kyu Chang ^f   Kim, Young Il ^k   Chung, Choon Hee ^l   Park, Tae Sun ^m   Lee, Jee Hyun ^c   Lee, Moon Kyu ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Sanofi Korea   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g Inje University   (South Korea)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ CHA University   (South Korea)

^j Ajou University School of Medicine   (South Korea)

^k Ulsan University College of Medicine   (South Korea)

^l Yonsei University Wonju College of Medicine   (South Korea)

^m Chonbuk National University Medical School   (South Korea)

more..

Author keywords

Basal prandial; Glargine; Glulisine; Premixed insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN LISPRO;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; TIME FACTOR;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; MALE; TIME FACTORS;

EID: 84933574361     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12312     Document Type: Article

References (13)

1. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes. 1995; 44: 1249-1258.
2. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281: 2005-2012.
4. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study I. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-3086.
5. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: A 6-month "proof-of-concept" study. Diabetes Obes Metab. 2011; 13: 1020-1027.
6. Song KH, Kim JM, Noh JH etal. Efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in Korea: A multicenter, open-label, single-arm study. Diabetes Metab J. 2013; 37: 117-124.
7. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: An evidence-based comparison. Clin Ther. 2007; 29: 1254-1270.
8. Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: Twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab. 2014; 16: 396-402.
9. Tinahones FJ, Gross JL, Onaca A, Cleall S, Rodriguez A. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: A randomized Phase IV trial. Diabetes Obes Metab. 2014; 16: 963-970.
10. Lee BW, Kang HW, Heo JS etal. Insulin secretory defect plays a major role in the development of diabetes in patients with distal pancreatectomy. Metabolism. 2006; 55: 135-141.
11. Hu FB. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care. 2011; 34: 1249-1257.
12. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C (ed.). Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Harwood Academic Publishers, Chur, 1994, 111-132.
13. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): A randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014; 2: 30-37.